Literature DB >> 12527574

The noninvasive staging of non-small cell lung cancer: the guidelines.

Gerard A Silvestri1, Lynn T Tanoue, Mitchell L Margolis, John Barker, Frank Detterbeck.   

Abstract

Correctly staging lung cancer is extremely important because the treatment options and the prognosis differ significantly by stage. Several noninvasive imaging studies are available to aid in identifying disease both within and outside of the chest. Chest CT scanning is useful in providing anatomic detail that better identifies the location of the tumor, its proximity to local structures, and whether or not lymph nodes in the mediastinum are enlarged. Unfortunately, the accuracy of chest CT scanning in differentiating benign from malignant lymph nodes in the mediastinum is unacceptably low. Whole-body positron emission tomography (PET) scanning provides functional information on tissue activity and has much better sensitivity and specificity than chest CT scanning for staging lung cancer in the mediastinum. In addition, metastatic disease can be detected by PET scan. Still, positive findings of PET scans can occur from nonmalignant etiologies (eg, infections), so that tissue sampling to confirm the suspected malignancy must be performed. The clinical evaluation tool, which is composed of a thorough history and physical examination, remains the best predictor of metastatic disease. If the findings from the clinical evaluation are negative, then imaging studies such as a CT scan of the head, a bone scan, or an abdominal CT scan are unnecessary, and the search for metastatic disease is complete. If signs, symptoms, or findings from the physical examination suggest the presence of malignancy, then sequential imaging, starting with the most appropriate study based on the clues obtained by the clinical evaluation, should be performed. Abnormalities detected by all of the aforementioned imaging studies are not always cancer. Unless overwhelming evidence of metastatic disease is present on an imaging study, in situations in which it will make a difference in treatment, all abnormal scan findings require tissue confirmation of malignancy so that patients are not precluded from having potentially curative surgery.

Entities:  

Mesh:

Year:  2003        PMID: 12527574     DOI: 10.1378/chest.123.1_suppl.147s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  37 in total

1.  Do we need randomised trials to evaluate diagnostic procedures? For.

Authors:  H Van Tinteren; O S Hoekstra; M Boers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-29       Impact factor: 9.236

2.  Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: prospective study.

Authors:  Martin Hetzel; Juergen Hetzel; Coskun Arslandemir; Karin Nüssle; Holger Schirrmeister
Journal:  BMJ       Date:  2004-05-01

3.  Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV.

Authors:  C C Henke; J Cabri; L Fricke; W Pankow; G Kandilakis; P C Feyer; M de Wit
Journal:  Support Care Cancer       Date:  2013-09-01       Impact factor: 3.603

4.  Electromagnetic navigation diagnostic bronchoscopy: a prospective study.

Authors:  Thomas R Gildea; Peter J Mazzone; Demet Karnak; Moulay Meziane; Atul C Mehta
Journal:  Am J Respir Crit Care Med       Date:  2006-07-27       Impact factor: 21.405

5.  The war on cancer: a report from the front lines.

Authors:  Gavin Melmed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

Review 6.  Carcinoma of the bronchus 60 years later.

Authors:  G A Silvestri; S G Spiro
Journal:  Thorax       Date:  2006-12       Impact factor: 9.139

7.  Electromagnetic navigation bronchoscopy in combination with PET-CT and rapid on-site cytopathologic examination for diagnosis of peripheral lung lesions.

Authors:  Bernd Lamprecht; Peter Porsch; Christian Pirich; Michael Studnicka
Journal:  Lung       Date:  2008-10-05       Impact factor: 2.584

8.  Perioperative analysis of biopsies issued from mediastinoscopy.

Authors:  M Alifano; M C Charpentier; C Perrotin; T J Molina; P Magdeleinat; J Audouin; J-F Regnard; S Camilleri-Broët
Journal:  Surg Endosc       Date:  2005-09-30       Impact factor: 4.584

9.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

10.  Clinical outcome of posterior fixation surgery in patients with vertebral metastasis of lung cancer.

Authors:  Tomoyuki Igarashi; Keigo Okamoto; Koji Teramoto; Ryosuke Kaku; Keiko Ishida; Keiko Ueda; Yo Kawaguchi; Tetsuo Hori; Masayuki Hashimoto; Shoji Kitamura; Noriaki Tezuka; Jun Hanaoka
Journal:  Mol Clin Oncol       Date:  2017-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.